Early intervention in myelofibrosis and impact on outcomes: A pooled analysis of the COMFORT-I and COMFORT-II studies

Medicine and Dentistry

• Patient 100%
• Ruxolitinib 45%
• Therapeutic Procedure 25%
• Myelofibrosis 20%
• Overall Survival 16%
• Combination Therapy 12%
• Diagnosis 12%
• Symptom 12%
• Disease Duration 12%
• Spleen 12%
• Diseases 8%
• Pooled Analysis 8%
• Analysis 8%
• Clinical Trial 8%
• Hazard Ratio 4%
• Logistic Regression Analysis 4%
• Population 4%
• Post-Hoc Analysis 4%
• Early Intervention 4%
• Thrombocytopenia 4%
• Cytopenia 4%
• Splenomegaly 4%
• Anemia 4%
• Drug 4%
• Chemotherapeutic Agent 4%
• Fatigue 4%
• Age 4%
• Janus Kinase Inhibitor 4%
• Bone Marrow Cancer 4%
• Language 4%

Nursing and Health Professions

• Ruxolitinib 45%
• Myelofibrosis 20%
• Overall Survival 16%
• Placebo 16%
• Adult 16%
• Diagnosis 12%
• Combination Therapy 12%
• Symptom 12%
• Volume 12%
• Disease Duration 12%
• Diseases 8%
• Analysis 8%
• Clinical Outcome 4%
• Anemia 4%
• Post Hoc Analysis 4%
• Population 4%
• Early Intervention 4%
• Standard 4%
• Randomization 4%
• Splenomegaly 4%
• Thrombocytopenia 4%
• Janus Kinase Inhibitor 4%
• Drug 4%
• Fatigue 4%
• Procedures 4%
• Cytopenia 4%
• Confounding Factor 4%